Segments (Tables)

12 Months Ended

Dec. 31, 2025

Segments [Abstract]

Schedule of Information by Segment of the Operations for the Year Ended

The following table presents summarized information by segment of the operations for the year ended December 31, 2025:

		Internet hospital				Pharmaceutical supply chain				Total
		RMB				RMB				RMB
Net revenue			150,712,158				249,202,806				399,914,964
Less:
Cost of revenues			(101,429,782	)			(246,203,071	)			(347,632,853	)
Salaries and welfare			(22,158,776	)			(2,694,321	)			(24,853,097	)
Commissions to doctors			(29,816,464	)			—				(29,816,464	)
Consultancy and professional service fees			(21,758,632	)			—				(21,758,632	)
Advertising and promotion costs			(17,461,881	)			(2,078,012	)			(19,539,893	)
Contracted development and research service fees			(9,919,840	)			—				(9,919,840	)
Other segment items*			(14,157,525	)			(2,039,392	)			(16,196,917	)
Segment loss			(65,990,742	)			(3,811,990	)			(69,802,732	)

Reconciliation of segment loss:
Impairment on long-lived assets and long-term assets											(2,108,517	)
Other professional service fees											(46,723,571	)
Other income											496,122
Other expense											(60,325	)
Interest expense											(12,885,122	)
Government grants											152,599
Loss before income tax											(130,931,546	)

		Internet hospital				Pharmaceutical supply chain				Total
		US$				US$				US$
Net revenue			21,551,552				35,635,527				57,187,079
Less:
Cost of revenues			(14,504,266	)			(35,206,571	)			(49,710,837	)
Salaries and welfare			(3,168,663	)			(385,283	)			(3,553,946	)
Commissions to doctors			(4,263,698	)			—				(4,263,698	)
Consultancy and professional service fees			(3,111,443	)			—				(3,111,443	)
Advertising and promotion costs			(2,497,016	)			(297,152	)			(2,794,168	)
Contracted development and research service fees			(1,418,518	)			—				(1,418,518	)
Other segment items*			(2,024,498	)			(291,629	)			(2,316,127	)
Segment loss			(9,436,550	)			(545,108	)			(9,981,658	)

Reconciliation of segment loss:
Impairment on long-lived assets and long-term assets											(301,514	)
Other professional service fees											(6,681,382	)
Other income											70,945
Other expense											(8,625	)
Interest expense											(1,842,548	)
Government grants											21,821
Loss before income tax											(18,722,961	)

*	For each reportable segment, the other segment item category primarily includes shipping expenses, rental costs, entertainment expense, office expense and expected credit losses.

The following table presents summarized information by segment of the operations for the year ended December 31, 2024:

		Internet hospital				Pharmaceutical supply chain				Total
		RMB				RMB				RMB
Net revenue			89,039,600				253,518,320				342,557,920
Less:
Cost of revenues			(50,986,600	)			(243,877,267	)			(294,863,867	)
Salaries and welfare			(19,590,201	)			(2,185,872	)			(21,776,073	)
Commissions to doctors			(22,685,703	)			—				(22,685,703	)
Consultancy and professional service fees			(3,660,677	)			—				(3,660,677	)
Advertising and promotion costs			(5,278,798	)			(5,824,158	)			(11,102,956	)
Other segment items*			(9,874,409	)			(2,146,990	)			(12,021,399	)
Segment loss			(23,036,788	)			(515,967	)			(23,552,755	)

Reconciliation of segment loss:
Impairment on long-lived assets and long-term assets											(2,238,525	)
Other income											1,238,538
Other expense											(37,608	)
Interest expense											(12,964,584	)
Government grants											189,500
Loss before income tax											(37,365,434	)

*	For each reportable segment, the other segment item category primarily includes shipping expenses, rental costs, entertainment expense, office expense and expected credit losses.

The following table presents summarized information by segment of the operations for the year ended December 31, 2023:

		Internet hospital				Pharmaceutical supply chain				Total
		RMB				RMB				RMB
Net revenue			71,008,971				233,844,000				304,852,971
Less:
Cost of revenues			(35,453,130	)			(230,678,072	)			(266,131,202	)
Salaries and welfare			(18,773,633	)			(1,827,887	)			(20,601,520	)
Commissions to doctors			(20,318,748	)			—				(20,318,748	)
Consultancy and professional service fees			(4,845,206	)			(10,891	)			(4,856,097	)
Advertising and promotion costs			(1,882,755	)			(1,549,237	)			(3,431,992	)
Other segment items*			(6,722,909	)			(3,432,378	)			(10,155,287	)
Segment loss			(16,987,410	)			(3,654,465	)			(20,641,875	)

Reconciliation of segment loss:
Impairment on long-lived assets and long-term assets											(1,607,027	)
Other income											163,622
Other expense											(1,336,595	)
Interest expense											(13,849,119	)
Government grants											321,573
Loss before income tax											(36,949,421	)

*	For each reportable segment, the other segment item category primarily includes shipping expenses, rental costs, entertainment expense, office expense and expected credit losses.

Schedule of Net Revenue from External Customers

In accordance with the enterprise-wide disclosure requirements, the Group’s net revenue from external customers through Internet hospital by main product category is as follows:

		For the Years Ended December 31,
		2023				2024				2025				2025
		RMB				RMB				RMB				US$
Prescription drugs			67,301,663				86,286,745				147,487,107				21,090,376
Over-the-counter (“OTC”) medicines			2,048,701				1,339,001				1,360,785				194,590
Traditional Chinese medicine (“TCM”)			23,574				51,208				284,980				40,752
Medical apparatus and instruments (“MAAI”)			130,333				75,821				28,691				4,103
Online consultation			1,364,274				1,190,397				1,477,013				211,210
Others			140,426				96,428				73,582				10,521
Total			71,008,971				89,039,600				150,712,158				21,551,552

The Group’s net revenue from external customers through pharmaceutical supply chain by main product category is as follows:

		For the Years Ended December 31,
		2023				2024				2025				2025
		RMB				RMB				RMB				US$
Prescription drugs			73,858,618				172,819,516				174,091,475				24,894,750
Over-the-counter (“OTC”) medicines			152,775,949				70,314,728				68,792,125				9,837,143
Traditional Chinese medicine (“TCM”)			3,618,690				5,991,329				201,676				28,839
Medical apparatus and instruments (“MAAI”)			143,199				112,228				2,994,468				428,203
Others			3,447,544				4,280,519				3,123,062				446,592
Total			233,844,000				253,518,320				249,202,806				35,635,527

Schedule of Total Segment Assets Reconciled to Combined Amounts

Total segment assets exclude corporate assets, such as cash and cash equivalents, amounts due from related parties, other non-current assets and deferred offering costs. Total segment assets reconciled to combined amounts are as follows: As of December 31, 2024 2025 2025 RMB RMB US$ Assets Total assets for reportable segments 24,674,093 92,995,788 13,298,222 Unallocated assets 21,553,493 14,561,638 2,082,287 Total combined assets 46,227,586 107,557,426 15,380,509